Innovent’s sintilimab receives first positive EMA opinion in Europe
AI Summary- Innovent Biologics reached a key milestone for sintilimab in European regulatory review.
- CHMP issued the drug’s first positive opinion under the European brand name Zybrivo.
- The EMA’s Committee for Medicinal Products for Human Use issued the opinion.